EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients
Year: 2015
Type: article
Authors: Jeffrey H. Lipton, Charles Chuah, Agnes Guerci-Bresler, Gianantonio Rosti, David Simpson, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Frank G. Haluska, Michele Baccarani, Jorge E. Cortes, Francois Guilhot, Andreas Hochhaus, Timothy P. Hughes, Hagop Kantarjian, Neil P. Shah, Moshe Talpaz, Michael W. Deininger
Institutions: University of Toronto, Princess Margaret Cancer Centre, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, North Shore Hospital, ARIAD Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center, Jena University Hospital, South Australia Pathology, University of California, San Francisco, University of Michigan, U-M Rogel Cancer Center, Huntsman Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2231281996